Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 6/20 | 0.55 |
| ▸ | CHRNB2 | P17787 | 5/20 | 0.55 |
| ▸ | CHRNA4 | P43681 | 5/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.55 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.55 |
| ▸ | GRM5 | P41594 | 5/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.53 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30694380 | 1.00 | CYP2A6 (0.55) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL31510379 | 0.91 | GRM5 (0.55) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3796332 | 0.82 | CYP2A6 (0.67) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL30825998 | 0.81 | GRM5 (0.49) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL3348980 | 0.81 | GRM5 (0.56) | CYP2A6GRM5CYP3A4CYP1A2 | |
| SCHEMBL17536620 | 0.80 | GRM5 (0.47) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL12750950 | 0.80 | GRM5 (0.39) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL12814022 | 0.79 | CYP2A6 (0.50) | CYP2A6CHRNB2CHRNA4CYP2C9CYP2B6 | |
| SCHEMBL29993685 | 0.78 | — | — | |
| SCHEMBL965118 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | claimed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | claimed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-RE49735-E1 | Oxazolidinones as modulators of MGLUR5 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-11-28 | — | — | US | disclosed |
| US-11572434-B2 | Curable composition, method for producing same, and article using same | DAIKIN INDUSTRIES, LTD. (JP) | 2023-02-07 | — | — | US | disclosed |
| CN-111416154-B | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2021-08-06 | — | — | CN | disclosed |
| US-20210189052-A1 | CURABLE COMPOSITION, METHOD FOR PRODUCING SAME, AND ARTICLE USING SAME | DAIKIN INDUSTRIES, LTD. (JP) | 2021-06-24 | — | — | US | disclosed |
| US-10781335-B2 | Functional film | DAIKIN INDUSTRIES, LTD. (JP) | 2020-09-22 | — | — | US | disclosed |
| US-10731048-B2 | — | — | 2020-08-04 | — | — | US | disclosed |
| CN-111416154-A | Silicon-based pyridine additive for high-voltage lithium ion battery electrolyte, electrolyte and battery | 松山湖材料实验室 | 2020-07-14 | — | — | CN | disclosed |
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-04-08 | — | — | US | disclosed |
| US-6673797-B1 | CYCLOOXYGENASE-2 INHIBITORS; TREATING INFLAMMATORY DISEASE INDUCED BY CYCLOOXYGENASE-2 | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-01-06 | — | — | US | disclosed |
| EP-1086950-A1 | HETEROCYCLIC INDOLE DERIVATIVES AND MONO- OR DIAZAINDOLE DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2001-03-28 | — | — | EP | disclosed |
| EP-0888340-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | Abbott Laboratories (US) | 1999-01-07 | — | — | EP | disclosed |
| US-5710157-A | INSECTICIDES FOR AGRICULTURE | FMC CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997030046-A1 | 4-(BENZO-1,3-DIOXOLYL)-PYRROLIDINE-3-CARBOXYLIC ACID DERIVATIVES AS ENDOTHELIN ANTAGONISTS | ABBOTT LABORATORIES (US) | 1997-08-21 | — | — | WO | disclosed |
| US-5593998-A | 2,4-diamino-5,6-disubstituted-and 5,6,7-trisubstituted-5-deazapteridines as insecticides | FMC CORPORATION (US) | 1997-01-14 | — | — | US | disclosed |
| US-5547954-A | MIXED WITH AGRICULTURAL ACCEPTABLE CARRIER | FMC CORPORATION (US) | 1996-08-20 | — | — | US | disclosed |
| US-5532370-A | FOR INSECTS INCLUDING LARVAE SUCH AS TOBACCO BUDWORM | FMC CORPORATION (US) | 1996-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040067964-A1 | Indole derivative having heterocycle and mono- or diazaindole derivative | IDO1, PTGS1, IDO2 | CYP2A6 112/4885CHRNB2 2942/4885CHRNA4 3423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.